Joseph Shulman - 09 Feb 2022 Form 3 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Technical Officer
Signature
/s/ Hunter Smith, attorney-in-fact for Joseph Shulman
Issuer symbol
RYTM
Transactions as of
09 Feb 2022
Net transactions value
$0
Form type
3
Filing time
11 Feb 2022, 20:30:39 UTC
Next filing
15 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RYTM Stock Option (Right to Buy) 09 Feb 2022 Common Stock 85,000 $21.38 Direct F1
holding RYTM Stock Option (Right to Buy) 09 Feb 2022 Common Stock 37,500 $30.66 Direct F2
holding RYTM Restricted Stock Units 09 Feb 2022 Common Stock 6,250 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F2 The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F3 The restricted stock units vest as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.
F4 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney